D Jeffrey Keyser Acquires 48,544 Shares of Lantern Pharma (NASDAQ:LTRN) Stock

Lantern Pharma Inc. (NASDAQ:LTRN) Director D Jeffrey Keyser bought 48,544 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The stock was purchased at an average cost of $2.06 per share, for a total transaction of $100,000.64. Following the completion of the transaction, the director directly owned 94,303 shares in the company, valued at approximately $194,264.18. This trade represents a 106.09% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Lantern Pharma Trading Up 0.3%

Shares of LTRN opened at $3.14 on Friday. The firm has a market capitalization of $35.51 million, a P/E ratio of -2.00 and a beta of 2.10. The stock’s fifty day simple moving average is $2.22 and its 200 day simple moving average is $2.92. Lantern Pharma Inc. has a twelve month low of $1.11 and a twelve month high of $5.74.

Lantern Pharma (NASDAQ:LTRN) last issued its earnings results on Friday, May 15th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.06.

Wall Street Analysts Forecast Growth

Several research analysts have commented on LTRN shares. Wall Street Zen raised Lantern Pharma to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings raised Lantern Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, May 7th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Institutional Trading of Lantern Pharma

Several large investors have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of Lantern Pharma by 5.6% during the third quarter. Vanguard Group Inc. now owns 384,041 shares of the company’s stock valued at $1,671,000 after acquiring an additional 20,321 shares in the last quarter. CM Management LLC grew its stake in shares of Lantern Pharma by 12.5% during the third quarter. CM Management LLC now owns 225,000 shares of the company’s stock valued at $979,000 after acquiring an additional 25,000 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Lantern Pharma by 5.1% during the first quarter. Renaissance Technologies LLC now owns 116,000 shares of the company’s stock valued at $159,000 after acquiring an additional 5,600 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Lantern Pharma by 5.1% during the fourth quarter. Geode Capital Management LLC now owns 96,742 shares of the company’s stock valued at $293,000 after acquiring an additional 4,661 shares in the last quarter. Finally, Susquehanna International Group LLP acquired a new stake in shares of Lantern Pharma during the third quarter valued at about $170,000. 28.62% of the stock is currently owned by institutional investors and hedge funds.

About Lantern Pharma

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.